Tele: 561.316.3330
Breaking Medical Device News

Friday, October 15, 2021
HomeFDANerivio Receives FDA Clearance of Expanded Indication to Cover Chronic Migraine Patients...

Nerivio Receives FDA Clearance of Expanded Indication to Cover Chronic Migraine Patients Reports Theranica

October 26, 2020

Nerivio has received FDA clearance of expanded indication to cover chronic migraine in people 18 years and older. The news was announced today by Theranica.

Nerivio now has clearance for use in acute treatment of migraine with or without aura in patients 18 years of age or older, without limitation to episodic migraine. The clearance is supported by results from two clinical studies with chronic migraine patients.

“The updated Nerivio indication is an important development for patients with chronic migraine” said Prof. Stephen Silberstein, MD, director of the Headache Center at the Jefferson University Hospital in Philadelphia, who also serves on Theranica’s Medical Advisory Board. “When chronic patients find an effective treatment, they must limit its use every month to avoid loss of effectiveness and a risk of medication overuse headache. Availability of an additional treatment option such as Nerivio provides an important additional tool to address this patient population.”

Prof. Silberstein further commented, “with over one thousand treatments by 130 chronic migraine patients across two open-label studies with Nerivio, the data is clinically relevant.”

There are four million chronic migraine patients in the United States. Each year, around 2.5% of the 38 million people with episodic migraine transition into chronic migraine.

Chronic migraine is defined by at least 15 headache days per month, eight of which are migraine. Most acute migraine prescription pharmaceuticals have a limit of eight to ten monthly doses to avoid medication overuse headache (MOH). This new indication offers people with chronic migraine a non-pharmaceutical treatment option. Nerivio has been shown in clinical trials and a largescale post-market surveillance to have efficacy in treating migraine similar to prescribed migraine medicine, without risks of medication overuse.

“It is so important for people living with chronic migraine to now have access to this effective non-pharmacological therapy”, said Nancy Harris Bonk, a migraine patient advocate, and educator, who serves as Chief Operating Officer of Chronic Migraine Awareness, Inc. “With migraine attacks occurring so frequently, we, people with chronic migraine, need to be mindful of overusing medications and identify the right individual balance of therapies that allows us to carry on with our daily routines.”

Theranica’s FDA-cleared prescribed therapeutic wearable Nerivio uses Remote Electrical Neuromodulation (REN) to activate the brain’s Conditioned Pain Modulation (CPM) (an intrinsic Pain Inhibition Mechanism) to treat pain and accompanying migraine symptoms. Nerivio is one of TIME’s best inventions of 2019.

“Since the neurotransmitters released as a result of REN triggering the CPM mechanism are strong analgesics, it is not surprising to see evidence that this treatment approach is effective in chronic migraine patients as well,” said Rami Burstein, PhD., professor of Anesthesia, Harvard Medical School, and Vice-Chair of Neuroscience in the Department of Anesthesia, Critical Care and Pain Medicine in Beth Israel Deaconess Medical Center in Boston, who also serves on Theranica’s medical advisory board.

“With this indication expansion, Theranica is now broadening market access of Nerivio in the USA, including health insurance reimbursement,” said Theranica CEO Alon Ironi. “It’s time to provide physicians and patients affordable access to a safe non-pharmacological acute treatment.”

Currently, a Nerivio prescription can be obtained through any licensed healthcare provider, including via online telemedicine consultation platforms. Nerivio is delivered directly to the patient’s home. Each Nerivio is good for 12 treatments, after which it can be recycled, and the prescription refilled with a new dispensed device.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy